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Abstract
Background: For more than a decade there has been increasing interest in the use of nanotechnology and
microarray platforms for diagnostic applications. In this report, we describe a rapid and simple gold nanoparticle
(NP)-based genomic microarray assay for specific identification of avian influenza virus H5N1 and its discrimination
from other major influenza A virus strains (H1N1, H3N2).
Results: Capture and intermediate oligonucleotides were designed based on the consensus sequences of the
matrix (M) gene of H1N1, H3N2 and H5N1 viruses, and sequences specific for the hemaglutinin (HA) and
neuraminidase (NA) genes of the H5N1 virus. Viral RNA was detected within 2.5 hours using capture-target-
intermediate oligonucleotide hybridization and gold NP-mediated silver staining in the absence of RNA
fragmentation, target amplification, and enzymatic reactions. The lower limit of detection (LOD) of the assay was
less than 100 fM for purified PCR fragments and 10
3 TCID50 units for H5N1 viral RNA.
Conclusions: The NP-based microarray assay was able to detect and distinguish H5N1 sequences from those of
major influenza A viruses (H1N1, H3N2). The new method described here may be useful for simultaneous detection
and subtyping of major influenza A viruses.
Background
Influenza A virus consists of eight negative single-stranded
RNA segments and can be classified into various subtypes
based on antigenic differences of two surface glycopro-
teins: hemagglutinin (HA) and neuraminidase (NA). A
total of 16 HA subtypes (H1-H16) and 9 NA subtypes
(N1-N9) have been identified. Many subtypes of influenza
virus are found in aquatic birds, and some of them have
been reported to infect humans [1-5]. The two most com-
mon subtypes of influenza A virus currently circulating in
humans are H1N1 and H3N2. The recent pandemic influ-
enza virus, a novel swine influenza A/H1N1 virus (2009 A
(H1N1)), which was first isolated in Mexico City in March
2009 [6], has spread to all states, and resulted in 9,079 hos-
pitalized cases and 593 deaths in the United States as of
September 11, 2009. In addition, highly pathogenic avian
influenza (HPAI) virus H5N1 has spread throughout Asia,
Europe, the Middle East and the African continent, and
was also documented to infect humans [3,7]. H5N1 virus
infection continues to progress with expanding host range
and poses a serious global threat [8]. Rapid and sensitive
diagnostic tools for the identification of influenza viruses
are crucial for early detection, appropriate treatment,
epidemiologic investigations, and timely responses to a
pandemic threat.
The most common methods for identification of influ-
enza A viruses mainly depend on virus isolation, culture,
characterization by polymerase chain reaction (PCR) and
hemagglutinin inhibition immunoassays, and require 3-7
days [8-11]. Nucleic acid testing (NAT) of influenza
viruses has been widely implemented over the last dec-
ade using target amplification methods such as reverse
transcription-PCR (RT-PCR), real-time RT-PCR, nucleic
acid sequence-based amplification and loop-mediated
isothermal amplification [12-15]. These technologies are
being employed for the rapid diagnosis of influenza A,
in particular the subtyping of the H5 gene [14,16-19].
For example, the Taqman influenza A/H5 Virus Detec-
tion Kit (Applied Biosystems, Foster City, CA), a PCR-
based method, was developed as an essential research
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subtypes of influenza viruses [20]. Additionally, Hoff-
mann et al. (2007) described a rapid real-time RT-PCR
test specific for the HPAI virus H5N1 (Qinghai clade
2.2) without the need for sequencing [21]. These meth-
ods use universal primers and probes to detect all sub-
types of influenza A, and specific primers and probes to
distinguish HA and NA gene subtypes in a simple, sin-
gle tube assay format following RNA isolation [13,14,18].
Microarray test methods have proven to be powerful
tools for viral identification and subtyping [2,22-25]. For
example, the FluChip microarray has been reported to
detect H1N1, H3N2 and H5N1 strains in less than
12 hours [22,26]. The MChip microarray was able to iden-
tify influenza A virus with 95% sensitivity and 92% specifi-
city [23,27]. CombiMatrix Corporation has also developed
a semiconductor-based Influenza A Research Microarray
that can detect all known subtypes of influenza A viruses
within 5 hours [28]. More recently, a low-density microar-
ray utilizing the NanoChip400 system (Nanogen Inc),
which employs one probe for the conserved M gene and
97 probes for the cleavage site region of HA gene, was
described to be a useful diagnostic tool for H5N1 virus
[29,30]. However, all of these microarray based assays
require two or more enzymatic amplification steps of
influenza viral RNA prior to hybridization. In addition,
detection requires labeling of multiple probes or incor-
poration of fluorescent dye- or biotin-conjugated nucleo-
tides into double-stranded DNA (dsDNA) generated by
RT-PCR. Moreover, the sensitivity of the conventional
microarray assay relies on the efficiency of target amplifi-
cation and hybridization of amplicons and probes. The
multiple steps involved in these assays make them compli-
cated, expensive, time consuming, susceptible to contami-
nation, and may produce false negative results due to the
presence of gene mutations, PCR inhibitors and RNA
degradation. The design of multiple, specific primer sets
and assay optimization pose major challenges [22].
In recent years there has been increasing interest in the
use of nanoparticles (NP) coupled with silver staining for
diagnostic applications [31-33] due to the higher sensitiv-
ities achievable by this approach compared with the
fluorescent dyes that are commonly used in microarray
assays. This modified microarray system allows direct
detection of single nucleotide polymorphisms (SNPs) in
human genomic DNA samples without the need for tem-
plate amplification [33]. In this report, we describe the
development of a new NP-based genomic microarray
assay that specifically identifies H5N1 viral nucleic acid
and simultaneously provides subtype identification of
influenza A virus in the absence of target amplification
procedures such as RT-PCR. The genomic microarray
system has a high degree of hybridization efficiency and
assay specificity. The method is also simple and rapid
since the H5N1 viral genomic RNA is added directly to
the slides for hybridization and can be detected using
gold NP probes.
Results
Probes for the NP-based microarray assay
Table 1 lists all capture and intermediate olignucleotide
(oligo) probes designed for this study. Three degenerate
capture oligos (M01, M02 and M03) were designed to
bind to the consensus M gene sequence region of influ-
enza A virus. An additional four capture oligos were
designed to specifically bind to sequences from the H5
and N1 genes, respectively. The 11 specific capture oli-
gos and a positive control oligo were synthesized and
printed on the array. For each gene, four or five inter-
mediate oligos that bind to a region adjacent to the cap-
ture sequences were designed and synthesized (refer to
Fig. 1 for assay scheme).
Specificity and sensitivity of the genomic microarray
assay
A typical NP-based genomic microarray assay is per-
formed by directly hybridizing purified viral RNA to the
capture oligos attached to the slide and then introducing
intermediate oligos with a poly-A tail to form a sandwich
complex (Fig. 1, Step 1). The complex is then incubated
with a poly dT-modified gold-NP probe that can bind to
the intermediate oligos and be stained with silver solu-
tion (Steps 2 and 3). The enhanced light-scattering signal
produced by the silver shell is detected by Nanosphere
Verigene® reader.
The detection sensitivity of the NP-based microarray
assay was first evaluated using M and H5 gene PCR ampli-
cons generated from the H5N1 virus strain ‘A/Vietnam/
1203/04’ (Fig. 2B). A dose-response model in the assay sig-
nal intensity was observed when the PCR products were
diluted from 100 pM to 100 fM, although different pat-
terns resulted between the M and H5 genes, and among
various capture oligos of the M gene. The M gene capture
oligos M01 and M03 could detect at least 100 fM of PCR
amplicon (S/CO = 6.2 ± 0.34 at 100 fM for capture M01)
while three of the four capture oligos of the H5 gene also
detected 100 fM of the H5 gene PCR amplicon (S/CO >1
at 100 fM for capture H502-H504). A third M gene cap-
ture oligo, M02, and the H5 gene capture oligo, H501,
could only detect 1 pM of the target. It is noteworthy that
the sensitivity of the assay is based on measurement of a
purified PCR amplicon which may be different from geno-
mic viral RNA (see below).
The PCR fragments of the M, H5 and N1 genes of
H5N1 virus (A/Vietnam/1203/04) were hybridized sepa-
rately or simultaneously to further evaluate the assay spe-
cificity (Fig. 2C). Specific signal was only generated in the
areas printed with the corresponding gene-specific
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ference was observed when multiple targets and inter-
mediate oligos were mixed and incubated simultaneously
(Fig. 2C, panel M+HA+NA). Therefore, the use of a
three-step capture and three-level hybridization proce-
dure in the current assay proved to be specific for detec-
tion of M, H5 and N1 genes of H5N1.
Direct detection of H5N1 viral RNA
The next set of experiments focused on directly detecting
viral RNA in the absence of enzymatic target amplification
using the gold NP-based microarray assay (Fig. 2D and
Table 2). The consensus M gene oligos within the micro-
array assay could detect the M gene from all three of the
major subtypes of influenza A viruses (H1N1, H3N2 and
H5N1) tested in our study. In addition, the N1 gene was
detected in both H1N1 (A/Hong Kong/29/06) and H5N1
(A/Vietnam/1203/04) viruses, and the H5 gene was only
detected in the H5N1 virus. No H5 or N1 signals were
observed for H3N2 virus (A/Hong Kong/8/68). The results
of 17 influenza A viruses tested for the M, H5 and N1
genes showed in Table 2. As a proof-of-concept experi-
ment, these results indicated that our assay conditions and
format permit the detection of different strains of H5N1
Table 1 Capture, intermediate and PCR oligos sequences
Oligo’s Name Target gene design purpose sequences (5’ to 3’)
M01** M capture CAGGTAGATRTTGAAAGATGAGYCTTCTAACCGAGGTCGA
M02** M capture TGACTCCCAGCAYMRGTCTCATAGGCAAATGGTGACAACA
M03** M capture AAGGCTATGGAGCARATGGCDGGATCRAGTGAGCARGCAG
H501 H5 capture TCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGC
H502 H5 capture CATACCCAACAATAAAGAGGAGCTACAATAATACCAACCA
H503 H5 capture TAGAGGGAGGATGGCAGGGAATGGTAGATGGTTGGTATGG
H504 H5 capture TTCCTAGATGTCTGGACTTATAATGCTGAACTTCTGGTTC
N101** N1 capture CAGYAAGGACAACAGTATAAGGATCGGTTCCARGGGGGAT
N102 N1 capture CATTAATGAGTTGTCCTGTGGGTGAGGCTCCCTCCCCATA
N103** N1 capture CCTAATTATCACTATGAGGARTGCTCCTGTTATCCTGATG
N104** N1 capture TGCATAAGACCTTGTTTCTGGGTTGAGTTRATCAGAGGGC
PCtrl1 capture ACTGTTTGTTATCTTGTTATCGTTATCTGA
Ipm01 M intermediate AAAGCCGAGATCGCACAGAGACTTGAAGATGTCTTTGCAG*
Ipm02 M intermediate AGCTCCAGTGCTGGTCTGAAAAATGATCTTCTTGAAAATT*
Ipm03 M intermediate GCCAAAGTCTATGAGGGAAGAATATCGAAAGGAACAGCAG*
Ipm04 M intermediate AATGGGGGTGCAGATGCAACGGTTCAAGTGATCCTCTCAC*
Ipm05 M intermediate CCACTAATCAGACATGAGAACAGAATGGTTTTAGCCAGCA*
Ipm06 H5 intermediate GACTATGAAGAATTGAAACACCTATTGAGCAGAATAAACC*
Ipm07 H5 intermediate TCCGTTGGGACATCAACACTAAACCAGAGATTGGTACCAA*
Ipm08 H5 intermediate AGGCAATAGATGGAGTCACCAATAAGGTCAACTCGATCAT*
Ipm09 H5 intermediate CATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGAC*
Ipm10 H5 intermediate ACTGGCAATCATGGTAGCTGGTCTATCCTTATGGATGTGC*
Ipn11 N1 intermediate AGAGAGCCGTTCATCTCATGCTCCCACTTGGAATGCAGAA*
Ipn12 N1 intermediate GAGTCTGTTGCTTGGTCRGCAAGTGCTTGCCATGATGGCA*
Ipn13 N1 intermediate TGTGCATGTGTAAATGGCTCTTGCTTTACTGTAATGACTG*
Ipn14 N1 intermediate AATCACATGTGTGTGCAGGGATAATTGGCATGGCTCAAAT*
Ipn15 N1 intermediate TCTTGGCCAGACGGTGCTGAGTTGCCATTCACCATTGACA*
aPCrl2 control probe TCAGATAACGATAACAAGATAACAAACAGT
bSZAM- M PCR AGTAGAAACAAGGTAGTTTTTT
MF M PCR TAGATATTGAAAGATGAGTC
HA5F H5 PCR GGTATAATCTGTCAAAATGGAGA
HA5R H5 PCR TAACTACAATCTGAACTCACAAAT
NA6F N1 PCR TCCAAATCAGAAGATAATAACCAT
NA6R N1 PCR GAATGGCAACTCAGCACCGTCT
* 25-mer poly (A) tail added at 3’ end of each intermediate oligonucleotides.
** M gene degenerated capture oligos from H1N1, H3N2 and H5N1.
a Gold NP was functionalized by PCrl2 oligo as a internal control probe.
bSequence from publication by Zou (1997) [36].
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subtypes of influenza A viruses H1N1, H3N2 and H5N1.
Due to the lack of well-characterized standards for
influenza A virus RNA, the detection sensitivity of the
NP-based microarray assay was evaluated by using two
different sources of viral RNA. First, the well-quantified
RNA transcribed from H1N1 M gene plasmid was used
in the experiments. The assay detected approximately
10
5 copies of transcribed RNA based on signals from
the M gene capture oligos M01 and M02 (data not
shown). Second, viral RNA extracted from the H5N1
strain A/Vietnam/1203/04 with quantified TCID50 units
was tested. Without RT-PCR amplification, the assay
detected 10
3 TCID50 units of viral RNA per reaction
with the specific H5, N1, and M gene capture oligos
based on a S/CO of >1 (Table 3). Statistical analysis
indicated that capture oligo N104 had the highest detec-
tion sensitivity for the A/Vietnam/1203/04 (H5N1)
strain. In a parallel experiment, the NP-based microar-
r a ya s s a ys h o w e d1 0
3 fold lower sensitivity compared
with the Taqman assay (data not shown).
Discussion
The conventional microarray assay requires target
amplification by PCR and incorporation of a fluores-
cent dye- or biotin-conjugated nucleotide into PCR
products prior to hybridization. These assays are both
time- and labor-consuming and challenging to perform
since multiple instruments are required for amplifica-
tion and detection. Special precautions are needed to
prevent carry-over contamination since detection of
the resulting PCR amplicons is not performed in the
same tube. In addition, RT-PCR may fail to amplify
the target gene due to the highly variable sequences
among influenza viruses [22], and multiple PCRs assays
may be required to determine the subtypes of influenza
A viruses. In this study, we developed a rapid, simple
gold NP-based microarray assay for the simultaneous
d e t e c t i o no fM ,H 5a n dN 1g e n e so fi n f l u e n z aAv i r u s
H5N1 and for differentiation of H5N1 from H1N1 and
H3N2 viruses. Our system combines specificity and
capability for multiplexed detection on a simplified
microarray platform, and may potentially be used in
resource-limited areas for monitoring or screening of
viral strains circulating during an influenza pandemic.
The unique advantages of the new system include: 1)
direct detection of viral RNA without involvement
of target amplification or other enzymatic steps; 2)
capture of a wide variety of strains by using multiple
capture oligos that target different viral genes and
sequences; 3) simultaneous detection and subtyping of
major influenza A viruses; 4) a relatively simple, and
rapid format. After RNA extraction, 20 samples can be
Figure 1 Simplified schematic overview of the gold nanoparticle
(NP)-based microarray assay. The target is whole viral genome
RNA (blue line), end modified capture oligos are 40 bp in length
(black line) printed on the amino-modified glass slide and
intermediate oligos are 65 bp in length (purple line) including 25-
mer poly (A) tail (red line). The probe is 15 nm gold nanoparticles
(NP) functionalized with poly dT tail (green line). The specific
hybridizations between the capture oligo, RNA (or DNA) and
intermediate oligo take place to form sandwich complexes in Step 1,
then the gold NP probes bind to the complexes in Step 2, and silver
staining is in Step 3.
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labor-intensive than previously reported assays such as
the FluChip [22,26], MChip [23,27] and NanoChip 400
[29,30], which usually require 5-12 hours for detection.
P r e l i m i n a r yd a t ai n d i c a t et h a tt h ea s s a yi sa b l et o
achieve a high degree of sensitivity without PCR amplifi-
cation. One reason is that the new detection method
utilizes gold NP-based silver enhancement, which pro-
vides higher sensitivity than the traditional fluorescent
labels. Another possible reason for higher detection sen-
sitivity is the use of multiple capture and intermediate
oligos to detect a target in multiple regions, which sig-
nificantly increases the binding of gold NPs and could
overcome the diagnostic challenge posed by potential
Figure 2 Image from a Verigene ID™ detection system. (A). Microarray layout with positive control capture (closed red circles on the top),
negative control which uses printing buffer as capture (closed yellow circles), M, H5, and N1 gene captures (filled as variable color of closed
circles, spotted in triplicate) are indicated. (B). The light shades represent strong silver staining signals. A portion of the microarray images for
DNA oligonucleotide following hybridization with PCR fragment are shown and light shades represent greater silver intensities for the M and H5
genes. The spots at the top of each array are positive controls. (C). Silver staining image for individual or multiple PCR products are shown and
labeled. (D). Typical genomic microarray silver staining image from 0.2 μg of H1N1, H3N2 or H5N1 viral RNA are shown. The boxed areas
highlight hits for specific subtypes.
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point-of-care settings with further modifications of the
detection systems. Indeed, the experiments we per-
formed showed that the microarray signals could be
visualized by the naked eye, without the need for a
device, when sufficiently high viral RNA copies are pre-
sent in the samples.
The genomic microarray assay involves three steps with
three levels of capture-target-intermediate oligo hybridi-
zation as indicated in Fig. 1. Our results demonstrate that
selection of target specific capture sequences is critical
for performance of this assay, and the use of multiple
capture and intermediate oligos is critical for detecting a
wide variety of strains with the desired sensitivity. Three
degenerate capture oligos for M gene (M01, M02 and
M03) were designed to identify the major influenza A
viruses (H1N1, H3N2 and H5N1) in our assay since the
M gene is relatively well-conserved among influenza A
viruses. Due to genetic variation of different virus strains,
the performance of the different capture oligos varied
(Fig. 2C and 2D). For example, A/Vietnam/1203/04
(H5N1) strain hybridized well with the M01 and M03
capture oligos but not with M02 (Fig. 2B and 2C). The
alignment of the three capture sequences with the M
gene sequence of A/Vietnam/1203/04 strain indicated
that there were two and four degenerate nucleotide sub-
stitutions in M01 and M03, respectively, but there were
three degenerate nucleotide substitutions and eleven
nucleotide mismatches in M02. This may explain why
M02 was not able to detect the A/Vietnam/1203/04
strain but performed well with other strains, including
H1N1 (Fig. 2D, A/Hong Kong/29/06), H3N2 (A/Hong
Kong/8/68), and certain H5N1 strains. Furthermore, the
same oligo design strategy was used for subtyping the H5
and N1 genes, and similar results were observed. For
example, the N1 gene capture oligo N104 can consis-
tently detect the majority of viral strains tested whereas
other N1 gene capture oligos exhibit more variation in
performance across strains. Nonetheless, capture oligo
N102 performed better than N104 in some H5N1 strains.
These results suggest that multiple captures are necessary
for improving detection sensitivity.
Using this multiple capture approach, the presence of
influenza A viral RNA was verified in all seventeen
strains of different influenza A viruses tested. The H5
gene was correctly identified in well-characterized H5N1
samples and the N1 gene was correctly identified in all
H5N1 and H1N1 samples tested. No cross-reactivity
was observed when other influenza A strains were
tested. These results demonstrate the specificity and
accuracy of our assay for detecting and subtyping H5N1
strains. Our current NP-based genomic array could
detect 10
3 TCID50 units of H5N1 virus per reaction,
which is within the range of proposed detection limits
for influenza diagnostics [34].
Conclusions
A novel, PCR-free, NP-based genomic microarray assay
for subtyping influenza A virus H5N1 was developed
and evaluated using different influenza A strains. Preli-
minary data indicate that the method may be useful in
surveillance and rapid identification of influenza A viral
infection, particularly during H5N1 outbreaks. This
proof-of-concept study provides evidence that the new
system may be used to characterize multiple influenza A
viruses during a pandemic and has the potential to
simultaneously detect multiple, major influenza A
viruses. We believe that assay sensitivity can be further
improved through sample enrichment and optimization
of assay conditions. Further studies are needed to vali-
date the current method with additional H5N1 strains
and clinical samples. The specific capture oligos for tar-
g e t i n gH 1 ,H 3 ,H 7 ,N 2 ,a n do t h e rg e n e si na d d i t i o n a l
influenza A viruses will be generated in the future to
expand the current identification panel. Thus, this new
Table 2 Results of genomic array detection of influenza A
viruses with specific captures
Specific Captures
Isolates Subtype H5 N1 M
A/Hong Kong/29/06 H1N1 - + +
A/Singapore/63/04 H1N1 - + +
A/Puerto Rico/8/34 H1N1 - + +
A/New Caledonia/20/99 H1N1 - + +
A/Hong Kong/8/68 H3N2 - - +
A/Wisconsin/67/05 H3N2 - - +
A/Panama/2007/99 H3N2 - - +
A/duck/Laos/3295/06 H5N1 + + +
A/Vietnam/1203/04 H5N1 + + +
A/Hong Kong/491/97 H5N1 + + +
A/Vietnam/1194/04 H5N1 + + +
A/Anhui/01/05 H5N1 + + +
A/Turkey/1/05 H5N1 + + +
A/Indonesia/05/05 H5N1 + + +
A/Turkey/Turkey/1/2005 H5N1 + + +
A/(H5) control antigen* H5N1 + + +
A/Duck/Laos-PR8/CBER-RG1 H5N1 + + +
*H5N1 strain obtained from CDC (VA2701, Inactivated H5N1).
Table 3 Signal/cutoff ratios of the H5N1 captures
relevant to virus titer






positive 42.7 ± 0.91 38.2 ± 2.11 40.2 ± 2.01 37.1 ± 2.12
H502 (H5) 38.9 ± 1.31 6.9 ± 0.30 1.3 ± 0.76 0.1 ± 0.11
N104 (N1) 43.6 ± 2.79 28.2 ± 0.07 4.8 ± 0.88 0.2 ± 0.16
M01 (M) 42.1 ± 2.60 6.0 ± 1.26 1.2 ± 0.41 0.1 ± 0.07
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to be rapidly modified to detect new targets. Since the
viral HA and NA genes of the recent outbreak of swine
influenza 2009 A(H1N1) are 27.2% and 18.2% distinct
respectively, in amino acid sequence, from the 2008
H1N1 strain [35], it is possible to modify this new NP-
based genomic microarray using specific oligos for the
2009 influenza A (H1N1) virus or other emerging pan-
demic influenza strains to facilitate identification and
differentiation of these viruses from other circulating
influenza A viral strains.
Methods
Samples and viral RNA extraction
Influenza virus isolates A/Hong Kong/29/06(H1N1), A/
Singapore/63/04 (H1N1), A/Hong Kong/8/68(H3N2),
A/Wisconsin/67/05(H3N2), H5N1 viruses (A/duck/
Laos/3295/06; A/Vietnam/1203/04; A/Hong Kong/
491/97; A/Vietnam/1194/04; A/Anhui/01/05; A/Turkey/
1/05 and A/Indonesia/05/05), were cultured in embryo-
nated chicken eggs in CBER, FDA. The plasmids pHW-
pr8M (H1N1), pCR-II Topo HA (H5N1) and pCR-II
Topo NA (H5N1) for HA, NA and M genes were pro-
vided by CDC (CDC, Atlanta, GA), some influenza virus
strains were purchased from ZeptoMetrix (ZeptoMetrix
corp., NY). Viral RNA of human immunodeficiency
virus type one (HIV-1) and West Nile virus (WNV) (iso-
late NY 2001-6263) were cultured in-house and served
as negative controls. Genomic viral RNA was extracted
directly from allantoic fluid or cell culture supernatant
with QIAamp Viral RNA Mini Kit (QIAGEN, Valencia,
CA). The purified RNA was quantified using NanoDrop
(NanoDrop Technologies, Inc. DE).
Primer design and RT-PCR
The PCR primers for M, H5 and N1 genes of H5N1 were
designed and listed in Table 1 [36]. H5N1 viral RNA
(A/Vietnam/1203/04) was first transcribed into cDNA
using SuperScript™ III First-Strand Synthesis System for
RT-PCR (Invitrogen, CA). cDNA was used as template to
perform a standard RT-PCR. The reaction mixture con-
sisted of 15 μl of 2× PCR Master Mix (Promega Corp.
WI), 25 pM of each forward and reverse primers, 2.0 μlo f
cDNA template. RNase free water was added to bring the
total volume to 30 μl. Amplification involved an initial
denaturation step at 95°C for 3 min, and 35 cycles of dena-
turation at 94°C for 30 sec, annealing at 50°C for 35 sec
and extension at 72°C for 1.5 min, followed by a final step
of extension at 72°C for 7 min. The PCR products were
electrophoresed on 1.0% agarose gel in Tris-acetate-EDTA
buffer. A 1.0 kb DNA ladder was used as a molecular
weight marker. The position of bands at 1747 bp, 1335 bp
and 1015 bp in agarose gel represented full length amplifi-
cation products of H5, N1 and M genes, respectively.
Capture and intermediate oligos
By using nucleotide sequences available in the Influenza
Primer Design Resource (IPDR) (http://www.ipdr.mcw.
edu/fludb/search), multiple sequence alignments of H5,
N1 and M genes were performed using MEGA 4 [37]
and Vector NTI Version 10 (Invitrogen, CA). Influenza
A virus RNA segment 7 encodes two matrix proteins
M1 and M2. The M1 protein is a highly conserved pro-
tein of 252-amino acids [38,39]. Multiple capture and
intermediate oligos complementary to the conserved
regions of M gene were selected from over 166 known
sequences corresponding to different subtypes of influ-
enza A viruses, including H1N1, H3N2 and H5N1,
whereas H5 oligos were chosen from the conserved
regions of over 40 known sequences of H5N1, and N1
oligos were selected from 42 known sequences for both
H1N1 and H5N1. Both capture and intermediate oligos
were also analyzed using the primer analysis software
(http://www.operon.com/oligos/toolkit.php) and Primer
Express 3.0 (Applied Biosystems, Foster City, CA) to
ensure no significant interference when they were mixed
and subjected to the same hybridization conditions. The
capture oligos we designed were modified with 5’-
Amino-C6-Modifier while a 25-mer poly (A) tail was
added at the 3’ end of intermediate oligos during the
synthesis at IDT Inc. (Integrated DNA Technologies,
IA). Selected capture/intermediate oligos were also
screened by mfold software (http://mfold.bioinfo.rpi.edu/
cgi-bin/rna-form1.cgi) [40] to prevent RNA secondary
structure from inhibiting hybridization. Capture oligos
which did not bind to any known sequences of influenza
A viruses were included as array internal controls [31].
Detailed information about the sequences of capture
and intermediate oligos used in this study is listed in
Table 1.
NP-based microarray assay
Target-specific capture oligo, positive-control oligo and
printing buffer (used as the negative control) were arrayed
onto CodeLink Activated slides (SurModics, Eden Prairie,
MN) at Nanosphere Inc. (Northbrook, IL) [31]. Each slide
contained 10 identical sub-arrays partitioned by a hybridi-
zation gasket, thus enabling 10 tests per slide. Aqueous
DNA-modified gold NP probe solutions were prepared
and supplied by Nanosphere Inc. 0.2-1.0 μg of viral RNA
samples and 10 nM of the intermediate oligos (final
concentration) were diluted in 100 μl final volume of
the hybridization buffer containing 5 × SSC (Invitrogen,
Carlsbad, CA), 0.05% sorbitan mono-9-octa decenoate
poly(oxy-1,1-ethanediyl), 0.05% Tween-20 (Sigma) and
40% formamide (Sigma), and applied to the microarray.
PCR amplicons were first denatured at 95°C for 5 min and
cooled down on ice for 2 min before loading. The arrays
were incubated for 90 min at 40°C with shaking at
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Page 7 of 9500 rpm in a hybridization oven (Step 1, Fig. 1). After the
incubation, the gasket was removed and slides soaked
three times in wash buffer A [0.5 N NaNO3, 0.01% SDS
and 0.05% Tween-20] and rinsed once in wash buffer B
[0.5 N NaNO3] and then dried. The NP probe solution
was incubated with the slide covered by a new hybridiza-
tion chamber for 30 min at 40°C (Step 2). After washing
with buffer B, the slides were stained with 2 ml of the mix-
ture of the Silver Enhancer A and B solutions (Nanosphere
Inc., Northbrook IL) for 7.5 min at room temperature
(Step 3). The light-scattering signal produced by the sil-
ver-enhanced gold NPs was captured by a photosensor
and converted to a TIFF image by using a Verigene Reader
(V1.1.6, Nanosphere, Inc.). The resulting TIFF images
were analyzed using GenePix 6 software (Molecular
Devices).
Determination of sensitivity and specificity
A serial dilution of the quantitated M gene and H5 gene
PCR amplicons (ranging from 100 to 0.1 pM) was ana-
lyzed using the NP-based microarray assay to determine
the limit of detection (LOD). The LOD was defined as
the lowest concentration at which a positive signal
could be detected. PCR fragments for H5, N1 and M
genes from the H5N1 strain (A/Vietnam/1203/04) were
loaded in the sub-array separately and simultaneously to
determine whether any cross-hybridization occurred.
Specificity of the multiplexed microarray assays was
evaluated by testing cross-reactivity with RNA extracted
from three subtypes of influenza A virus and other viral
pathogens such as HIV-1 and WNV.
Data analysis
For images collected by Verigene Reader, background
noise was subtracted from the raw images using Gene-
Pix 6.0 data analysis software. The cutoff value was the
sum of the means of the pixel intensity of three negative
controls plus 3 standard deviations (SD). Samples with
signal-to-cutoff (S/CO) ratios equal to or greater than
1.00 were considered positive.
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